ORIGINAL RESEARCH article
Front. Mol. Biosci.
Sec. Molecular Diagnostics and Therapeutics
Volume 12 - 2025 | doi: 10.3389/fmolb.2025.1594610
This article is part of the Research TopicIntegrative Multi-Omics Approaches for Predicting Immunotherapy Efficacy in Solid TumorsView all 5 articles
Integrative Multi-omics and Mendelian Randomization Analysis Reveal SPP1 + Tumor-Associated Macrophage-Driven Prognostic Signature for Hepatocellular Carcinoma
Provisionally accepted- 1The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
- 2Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi Province, China
- 3Hui Ya Hospital of The First Affiliaterd Hospital, Sun Yat-sen University, Huizhou, Guangdong Province, China
- 4Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
- 5Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
- 6Wuchuan People’s Hospital, ZhanJiang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: The SPP1 + tumor-associated macrophages (TAMs) have been implicated in tumor metastasis and immune evasion. However, the prognostic significance of SPP1 + TAMs in hepatocellular carcinoma (HCC) remains largely unexplored. This study aimed to identify SPP1 + TAMs-related genes and construct a model to predict overall survival (OS) in HCC patients.Methods: Single-cell RNA sequencing (scRNA-seq) datasets from HCC patients were analyzed to identify SPP1 + TAMs. SPP1 + TAMs-related risk score (STRS) was developed using Mendelian randomization (MR) analysis and Least Absolute Shrinkage and Selection Operator (LASSO) regression. HCC patients from the the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) cohorts were stratified into high-and low-STRS groups based on STRS. Kaplan-Meier survival analysis, receiver operating characteristic (ROC) curve analysis, and functional enrichment analysis were performed to assess the prognostic value of STRS.Results: SPP1 + TAMs exhibited strong associations with immunosuppressive functions. 16 SPP1 + TAMs-related genes were used to construct STRS. Patients in the high-STRS group had significantly worse OS than those in the low-STRS group (p<0.001). ROC analysis demonstrated robust predictive power, with AUC values ranging from 0.685 to 0.748 for 1-year OS, 0.717 to 0.739 for 2-year OS, and 0.719 to 0.738 for 3-year OS.The STRS model also exhibited strong predictive capability for the distinction of drug resistance.This study identified SPP1 + TAMs-related genes as key prognostic indicators in HCC. The STRS model provides an effective tool for predicting patient survival and may facilitate personalized treatment strategies for HCC. These findings 4 enhance the understanding of TAMs-driven immune modulation in HCC and highlight potential therapeutic targets for improving patient outcomes.
Keywords: Hepatocellular Carcinoma, SPP1 + TAMs, Mendelian randomization, Prognostic signature, UBE2I
Received: 16 Mar 2025; Accepted: 21 Apr 2025.
Copyright: © 2025 Lei, Lei, Wang, Ye, Liu, Chen, Zhou, Tan, Chen, Zhang and Tan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jiehui Tan, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510000, Guangdong Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.